142 related articles for article (PubMed ID: 16352560)
1. Expanded tropism and altered activation of a retroviral glycoprotein resistant to an entry inhibitor peptide.
Amberg SM; Netter RC; Simmons G; Bates P
J Virol; 2006 Jan; 80(1):353-9. PubMed ID: 16352560
[TBL] [Abstract][Full Text] [Related]
2. Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate.
Netter RC; Amberg SM; Balliet JW; Biscone MJ; Vermeulen A; Earp LJ; White JM; Bates P
J Virol; 2004 Dec; 78(24):13430-9. PubMed ID: 15564453
[TBL] [Abstract][Full Text] [Related]
3. Model of the TVA receptor determinants required for efficient infection by subgroup A avian sarcoma and leukosis viruses.
Melder DC; Pike GM; VanBrocklin MW; Federspiel MJ
J Virol; 2015 Feb; 89(4):2136-48. PubMed ID: 25473063
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of avian retroviral host range extension.
Rainey GJ; Natonson A; Maxfield LF; Coffin JM
J Virol; 2003 Jun; 77(12):6709-19. PubMed ID: 12767991
[TBL] [Abstract][Full Text] [Related]
5. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
6. Presence of a hypervariable region within the hr2 domain of the host range determining sequences of the envelope protein gp85 (SU) of subgroup-A avian sarcoma-leukosis viruses.
Hara H; Tanaka A; Kaji A
Virus Genes; 1996; 12(1):37-46. PubMed ID: 8879119
[TBL] [Abstract][Full Text] [Related]
7. Mutations in Both the Surface and Transmembrane Envelope Glycoproteins of the RAV-2 Subgroup B Avian Sarcoma and Leukosis Virus Are Required to Escape the Antiviral Effect of a Secreted Form of the Tvb
Yin X; Melder DC; Payne WS; Dodgson JB; Federspiel MJ
Viruses; 2019 May; 11(6):. PubMed ID: 31159208
[TBL] [Abstract][Full Text] [Related]
8. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
[TBL] [Abstract][Full Text] [Related]
9. Receptor-induced conformational changes in the SU subunit of the avian sarcoma/leukosis virus A envelope protein: implications for fusion activation.
Delos SE; Godby JA; White JM
J Virol; 2005 Mar; 79(6):3488-99. PubMed ID: 15731243
[TBL] [Abstract][Full Text] [Related]
10. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors.
Valsesia-Wittmann S; Drynda A; Deléage G; Aumailley M; Heard JM; Danos O; Verdier G; Cosset FL
J Virol; 1994 Jul; 68(7):4609-19. PubMed ID: 8207835
[TBL] [Abstract][Full Text] [Related]
11. Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein.
Bosch BJ; Rossen JW; Bartelink W; Zuurveen SJ; de Haan CA; Duquerroy S; Boucher CA; Rottier PJ
J Virol; 2008 Mar; 82(5):2580-5. PubMed ID: 18077706
[TBL] [Abstract][Full Text] [Related]
12. Substitutions in the receptor-binding domain of the avian sarcoma and leukosis virus envelope uncouple receptor-triggered structural rearrangements in the surface and transmembrane subunits.
Damico R; Rong L; Bates P
J Virol; 1999 Apr; 73(4):3087-94. PubMed ID: 10074159
[TBL] [Abstract][Full Text] [Related]
13. The hr1 and fusion peptide regions of the subgroup B avian sarcoma and leukosis virus envelope glycoprotein influence low pH-dependent membrane fusion.
Babel AR; Bruce J; Young JA
PLoS One; 2007 Jan; 2(1):e171. PubMed ID: 17245447
[TBL] [Abstract][Full Text] [Related]
14. Identification of glycosylation sites in the SU component of the Avian Sarcoma/Leukosis virus Envelope Glycoprotein (Subgroup A) by mass spectrometry.
Kvaratskhelia M; Clark PK; Hess S; Melder DC; Federspiel MJ; Hughes SH
Virology; 2004 Aug; 326(1):171-81. PubMed ID: 15262505
[TBL] [Abstract][Full Text] [Related]
15. A charged second-site mutation in the fusion peptide rescues replication of a mutant avian sarcoma and leukosis virus lacking critical cysteine residues flanking the internal fusion domain.
Melder DC; Yin X; Delos SE; Federspiel MJ
J Virol; 2009 Sep; 83(17):8575-86. PubMed ID: 19515762
[TBL] [Abstract][Full Text] [Related]
16. The central proline of an internal viral fusion peptide serves two important roles.
Delos SE; Gilbert JM; White JM
J Virol; 2000 Feb; 74(4):1686-93. PubMed ID: 10644338
[TBL] [Abstract][Full Text] [Related]
17. Changes in the SU can modulate the susceptibility of feline immunodeficiency virus to TM-derived entry inhibitors.
Giannecchini S; Pistello M; Del Santo B; Rovero P; Sichi O; Bendinelli M
New Microbiol; 2004 Apr; 27(2 Suppl 1):77-84. PubMed ID: 15646068
[TBL] [Abstract][Full Text] [Related]
18. Two different molecular defects in the Tva receptor gene explain the resistance of two tvar lines of chickens to infection by subgroup A avian sarcoma and leukosis viruses.
Elleder D; Melder DC; Trejbalova K; Svoboda J; Federspiel MJ
J Virol; 2004 Dec; 78(24):13489-500. PubMed ID: 15564460
[TBL] [Abstract][Full Text] [Related]
19. Role of basic residues in the subgroup-determining region of the subgroup A avian sarcoma and leukosis virus envelope in receptor binding and infection.
Rong L; Edinger A; Bates P
J Virol; 1997 May; 71(5):3458-65. PubMed ID: 9094617
[TBL] [Abstract][Full Text] [Related]
20. An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity.
Borrego P; Calado R; Marcelino JM; Pereira P; Quintas A; Barroso H; Taveira N
AIDS; 2013 Apr; 27(7):1081-90. PubMed ID: 23324659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
